STOCK TITAN
  1. Home
  2. News
  3. CSLLY

CSL Ltd. - CSLLY STOCK NEWS

Welcome to our dedicated news page for CSL Ltd. (Ticker: CSLLY), a resource for investors and traders seeking the latest updates and insights on CSL Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CSL Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CSL Ltd.'s position in the market.

News
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Rhea-AI Summary
CSL and Arcturus Therapeutics Announce Positive Phase 3 Results for ARCT-154 Sa-mRNA COVID-19 Vaccine
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
none
-
News
CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance
Rhea-AI Summary
CSL (ASX:CSL; USOTC:CSLLY) announced that the FDA has accepted the company's Biologics License Application for garadacimab as a once-monthly prophylactic treatment for hereditary angioedema (HAE). The European Medicines Agency has also accepted the submission for CSL's Marketing Authorization Application for garadacimab. If approved, garadacimab would become the first treatment for HAE in the U.S. and EU to target activated Factor XII (FXIIa), with orphan-drug designation granted by both the FDA and EMA. The BLA and MAA are supported by data from the pivotal VANGUARD trial, with the ongoing open-label extension evaluating the long-term safety and efficacy of garadacimab in patients with HAE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
none
-
News
CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B
Rhea-AI Summary
CSL (ASX: CSL; USOTC: CSLLY) announced the three-year results from the pivotal HOPE-B study confirming continued long-term durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb) gene therapy for hemophilia B. The treatment offers elevated and sustained factor IX activity levels for years, reducing the rate of annual bleeds and the need for regular prophylactic infusions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
none
News
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Rhea-AI Summary
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics receive historic approval for ARCT-154, the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine in Japan. This marks a significant milestone in CSL's promise to develop and deliver innovative vaccines to combat respiratory viral diseases, expanding their comprehensive portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
covid-19
-
News
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
Rhea-AI Summary
CSL (CSL; CSLLY) and Arcturus Therapeutics announced that Japan's Ministry of Health, Labor and Welfare granted approval for ARCT-154, a self-amplifying mRNA COVID-19 vaccine. This marks the first sa-mRNA vaccine in the world to be registered, highlighting CSL's commitment to global public health. The vaccine is approved for initial vaccination and booster for adults 18 years and older, based on positive clinical data from several studies. CSL Seqirus, in partnership with Meiji Seika Pharma, will distribute the vaccine in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
covid-19
-
News
Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
Rhea-AI Summary
On November 24, 2023, the global coalition for Iron Deficiency Day is focusing on the importance of early diagnosis and treatment of iron deficiency and anemia. This initiative aims to raise awareness about the serious health impact of these conditions and their effect on quality of life. The company involved in this initiative is not specified in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
none
News
CSL and uniQure Win 2023 Prix Galien USA Award
Rhea-AI Summary
Global biotechnology leader CSL and uniQure N.V. have won the 2023 Prix Galien USA Award for Best Product for Rare/Orphan Diseases for their gene therapy HEMGENIX®. HEMGENIX is the first and only FDA-approved gene therapy for adults with hemophilia B. It has also received conditional marketing authorization in the European Union and Canada.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
-
News
New Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines
Rhea-AI Summary
CSL Seqirus announces new data supporting the effectiveness and value of cell-based and adjuvanted seasonal influenza vaccines
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
none
-
News
CSL Seqirus Presents Real-World Evidence at ESWI Demonstrating the Impact of Influenza Vaccination Campaigns to Help Protect People and Healthcare Systems
Rhea-AI Summary
CSL Seqirus presents new real-world evidence studies on influenza vaccination at ESWI Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
none
News
CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine
Rhea-AI Summary
CSL Seqirus selected by BARDA to deliver H5N8 A/Astrakhan antigen to the U.S. government for pandemic response readiness
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
none
Stock CSLLY logo
CSL Ltd.

OTC:CSLLY

CSLLY Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CSLLY Stock Data

89.03B
482.67M
0.02%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Australia
Melbourne